Aratana Therapeutics Inc (PETX) : Awm Investment Company reduced its stake in Aratana Therapeutics Inc by 8.49% during the most recent quarter end. The investment management company now holds a total of 1,116,255 shares of Aratana Therapeutics Inc which is valued at $9,543,980 after selling 103,580 shares in Aratana Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Aug 9, 2016.Aratana Therapeutics Inc makes up approximately 1.87% of Awm Investment Company’s portfolio.
Other Hedge Funds, Including , Dimensional Fund Advisors Lp reduced its stake in PETX by selling 16,417 shares or 27.14% in the most recent quarter. The Hedge Fund company now holds 44,083 shares of PETX which is valued at $376,910. Sg Americas Securities sold out all of its stake in PETX during the most recent quarter. The investment firm sold 10,774 shares of PETX which is valued $86,192.California State Teachers Retirement System boosted its stake in PETX in the latest quarter, The investment management firm added 6,211 additional shares and now holds a total of 69,941 shares of Aratana Therapeutics Inc which is valued at $559,528. Simplex Trading added PETX to its portfolio by purchasing 7,163 company shares during the most recent quarter which is valued at $48,422. Aratana Therapeutics Inc makes up approx 0.01% of Simplex Trading’s portfolio.
Aratana Therapeutics Inc closed down -0.02 points or -0.22% at $8.96 with 8,48,500 shares getting traded on Wednesday. Post opening the session at $8.99, the shares hit an intraday low of $8.68 and an intraday high of $9.055 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Aratana Therapeutics Inc reported $0.61 EPS for the quarter, beating the analyst consensus estimate by $ 1.03 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.42.Analysts expectations of $ .12.During the same quarter in the previous year, the company posted $-0.23 EPS.
Many Wall Street Analysts have commented on Aratana Therapeutics Inc. Aratana Therapeutics Inc was Resumed by Jefferies to “Buy” on Aug 19, 2016.
Aratana Therapeutics Inc. is a pet therapeutics company focused on licensing developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions such as pain and inflammation stimulation of appetite cancer and other serious diseases for dogs and cats. These product candidates are in various stages of development for the treatment of cats or dogs or both. The Company’s target indications include pain and inflammation associated with osteoarthritis inappetence post-operative pain lymphoma osteosarcoma atopic dermatitis ocular herpes and feline immunodeficiency virus. The Company’s most advanced products from a development and commercialization perspective AT-004 and AT-005 are monoclonal antibodies (MAbs) for treating lymphoma in dogs.